- Details
- Description
-
Packaging Size30t/bottle
-
Strength40mg
-
CompositonAfatinib
-
TreatmentEGFR mutations non-small cell lung cancer (NSCLC)
-
FormTablet
-
BrandLuciAfa
-
Quantity Unit40mg*30T/bottle
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
INDICATIONS AND USAGE
Afatinib is a kinase inhibitor indicated for:
• First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Limitations of Use: Safety and efficacy of LuciAfa were not established in patients whose tumors have resistant EGFR mutations .
• Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy .
DOSAGE AND ADMINISTRATION
• Recommended dosage: 40 mg orally once daily.
• Renal impairment: 30 mg orally once daily in patients with severe renal impairment.
• Instruct patients to take LuciAfa at least 1 hour before or 2 hours after a meal.
